AI Drives Revolution in N-of-1 Personalized Medicine

Healthcare leaders at the 2026 Precision Medicine World Conference discussed how generative AI and protein-folding models are enabling the design of "N-of-1" drugs ^[1]. These medicines are tailored to specific genetic mutations found in individual patients ^[1]. This approach aims to transform treatments for rare diseases and cancer by targeting unique molecular structures ^[1]. Venture capitalist Vinod Khosla and other industry leaders emphasized that AI can model specific molecular binding for unique cases ^[1]. By doing so, AI tools may bypass traditional bottlenecks found in standard clinical trials ^[1]. This shift marks a new era in precision medicine where drug development focuses on the single patient ^[1].